Finance

Unfinished bridge
Biotech

When a new biotech’s drug pipeline is more of a ‘hypeline’

By Kate Sheridan

Pharmalot

Pharmalittle: Look who’s advising Nancy Pelosi on drug prices; Purdue tried to buy an opioid-addiction treatment business

By Ed Silverman

Pharmalot

Pharmalittle: J&J gets U.S. nod for first targeted bladder cancer drug; Allergan wins key support from advisory firms

By Ed Silverman

Pharmalot

Pharmalittle: Many employers want to eliminate rebates; Gilead takes another run at NASH

By Ed Silverman

Drug price jump
Pharmalot

A troubled drug maker attempts to compensate for its problems by taking huge price hikes

By Ed Silverman

Drug Pricing in America: A Prescription for Change, Part II
First Opinion

Value-based agreements could disrupt how we pay for new therapies

By Steve Brozak

Pharmalot

Pharmalittle: Oklahoma trims claims against J&J and Teva in opioid suit; House committee poised to vote on drug pricing bills

By Ed Silverman

iCarbonX offices
Business

U.S. forces health company to ditch Chinese investor, in sign of heightened concern over foreign influence

By Rebecca Robbins, Matthew Herper, and Damian Garde

Patrick Soon-Shiong
Pharmalot

A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme

By Ed Silverman

Pharmalot

Pharmalittle: Roche struggles to close Spark deal; Congress zeroes in on insulin makers

By Ed Silverman

Pharmalot

Pharmalittle: AIDS activists heckle CDC director; DEA calls Mallinckrodt an opioid ‘kingpin’

By Ed Silverman

Pharmalot

Pharmalittle: Vertex destroyed drugs amid standoff in the U.K.; Sacklers accused of diverting Purdue assets

By Ed Silverman

Foundation Medicine
Biotech

The ‘venture creation’ model is picking up speed as a way to fuel biotech

By Kate Sheridan

Pharmalot

Pharmalittle: Gilead and CDC tussle over Truvada patents; Novartis wins FDA approval for an MS drug

By Ed Silverman

Pharmalot

Pharmalittle: Purdue settles opioid lawsuit in Oklahoma; FTC wants more data on Bristol-Celgene deal

By Ed Silverman

Noubar Afeyan
Biotech

Flagship Pioneering raises $824 million in venture capital round, its most ever

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Pfizer pays $636 million for rights to gene therapies; Novartis denies bribing Greek officials

By Ed Silverman

Pharmalot

Pharmalittle: Bristol and Starboard duel over Celgene deal; one in five adults ask doctors for cheaper meds

By Ed Silverman

Dr. Steve Paul
Biotech

Biotech startup raises $68 million to further work on its treatment for schizophrenia

By Jonathan Saltzman — Boston Globe

Red blood cells
Biotech

Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?

By Matthew Herper

Pharmalot

Pharmalittle: A debate over using list prices in research; FDA fast-tracks a Purdue opioid overdose drug

By Ed Silverman

Pharmalot

Pharmalittle: Bristol CEO says Celgene deal is not defensive; FDA approves generic valsartan

By Ed Silverman

Pharmalot

Pharmalittle: Hospitals struggle to pay for CAR-T therapies; J&J was the opioid ‘kingpin’

By Ed Silverman

First Opinion

Biomarkup: creating or promoting medical tests to drive revenue

By Kenneth D. Mandl and Arjun K. Manrai

Bristol-Myers Squibb
Pharmalot

Bristol scrambles to push Celgene deal, but are the odds as high as some think?

By Ed Silverman

Earth's City Lights at Night
The Pharmalot View

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

By Ed Silverman

Hugh Hewitt
Politics

The $100,000 dark-money mystery group behind a pharma-bashing Facebook campaign

By Ike Swetlitz

Pharmalot

Pharmalittle: FDA approves new type of antidepressant; Bristol and fund issue dueling letters over Celgene deal

By Ed Silverman

STAT SPOTLIGHT
Biotech

Startup Spotlight: A Defense Department-backed biotech pushes platelets to clot blood

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy